Edited by Jürgen Borlak

WILEY-VCH

Handbook of Toxicogenomics

Strategies and Applications



Contents

Preface *V*

1 Introduction *1*
Jürgen Borlak

1.1 A Shift in Paradigm *1*
1.2 Enabling Technologies Lead to New Founded Knowledge in Genomic Science *3*
1.3 Translating RNAs Into Proteins *4*
1.4 Toxicogenomics – A Perspective *5*

Technology Platforms in Toxicogenomics

2 Expression Profiling using SAGE and cDNA Arrays *9*
Andreas Bosio

2.1 Introduction *9*
2.2 SAGE Technology *10*
2.2.1 Principles of SAGE Technology *10*
2.2.2 Generation of SAGE Libraries *11*
2.2.3 SAGE Bioinformatics *12*
2.2.4 SAGE Applications *13*
2.3 cDNA Arrays *14*
2.3.1 Principles of PIQOR Technology *14*
2.3.2 Selection and Annotation of Suitable cDNA Fragments *16*
2.3.3 Production of Microarrays *17*
2.3.4 Application of Microarrays *19*
2.3.5 Array Data: Acquisition, Analysis, and Mining *20*
2.4 Integrated Approaches using Microarrays *23*
2.5 Combination of Microarrays and SAGE *24*
References *25*

Handbook of Toxicogenomics: Strategies and Applications. Edited by Jürgen Borlak
Copyright © 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 3-527-30342-1

3 Oligo Arrays, Global Transcriptome Analysis *27*
Jacques Retief, Earl Hubbell, and David Finkelstein

3.1 Introduction to GeneChip® Microarray Technology *27*
3.1.1 Introduction to RNA Expression Microarrays *27*
3.1.2 GeneChip® RNA Expression Microarray Technology *27*
3.1.3 Biological Annotations *35*
3.1.4 Conclusions *43*
3.1.5 Introduction to GeneChip® DNA mapping microarrays *44*
3.1.6 GeneChip® DNA Mapping Microarray Technology *45*
3.1.7 Conclusion *47*
3.2 Experimental Design and Data Analysis *47*
3.2.1 Introduction *47*
3.2.2 Experimental Design *48*
3.2.3 Data Assessment and Correction *66*
3.2.4 Comparing Results *71*
3.2.5 Conclusions *77*
References 78

4 Toxicogenomics Applications of Open-platform High Density DNA Microarrays *83*
Mark McCormick and Emile F. Nuwaysir

4.1 Introduction *83*
4.2 Genome-scale Expression Profiling *87*
4.3 Multiplex Array Hybridization with NimbleScreen 12 *88*
4.4 NimbleScreen 4 *90*
4.5 Software for Open-platform Array Design *92*
4.6 Multiplex Array Control Elements *93*
4.7 Multiplex Array Consistency *93*
4.8 Conclusions *94*
References 99

5 Mass Spectrometry and Proteomics: Principles and Applications *97*
Uwe Rapp

5.1 Introduction *97*
5.2 Analysis Tools in Proteomics *98*
5.2.1 Separation Techniques *98*
5.2.2 Mass Spectrometric Techniques *99*
5.3 Application *100*
5.3.1 Experimental Details *100*
5.3.2 Results *101*
5.3.3 Top–Down Analysis *112*
5.4 Summary and Outlook *112*
References 113

6 Covalent Protein Modification Analysis by Electrospray Tandem Mass Spectrometry *115*
Wolf D. Lehmann

6.1 Introduction *115*
6.2 Electrospray Ionization *117*
6.3 Tandem Mass Spectrometry *117*
6.4 Q–TOF and Q–FT–ICR Systems *119*
6.4.1 Resolution *119*
6.4.2 Mass Accuracy *120*
6.5 Peptide Sequencing by Electrospray Tandem Mass Spectrometry *121*
6.6 Protein Modifications and their MS/MS Reactions *122*
6.7 Detection of Protein Modifications by MS and MS/MS *124*
6.7.1 Phosphorylation *126*
6.7.2 Tyrosine Sulfation *132*
6.7.3 Redox-related Modifications *132*
6.7.4 Myristoylation *132*
6.7.5 Acetylation *133*
6.7.6 Methylation *135*
6.7.7 Glycosylation *135*
6.7.8 Ubiquitination *135*
6.7.9 Isoaspartate Formation *136*
6.8 Summary and Outlook *136*
References *137*

7 Chromatin Immunoprecipitation-based Identification of Gene Regulatory Networks *143*
Monika Niehof and Jürgen Borlak

7.1 Introduction *143*
7.1.1 Importance of Identifying Transcriptional Regulatory Networks in Toxicogenomics *143*
7.1.2 Chromatin Immunoprecipitation to Analyze Target Genes *144*
7.2 Description of Methods *144*
7.2.1 Crosslinking Applications *144*
7.2.2 Chromatin Fragmentation *146*
7.2.3 Immunoprecipitation of Proteins *147*
7.2.4 DNA Isolation and PCR Analyses *148*
7.2.5 Cloning Strategies *148*
7.2.6 Target Validation *150*
7.3 Successfully Reported ChIP Cloning for New Target Identification *151*
7.4 Problems and Potential Strategies *153*
7.4.1 Elimination of Nonspecific DNA and Protein–Protein Crosslinking *153*
7.4.2 Enrichment of Target Promoters and High-throughput Screening *153*
7.5 Challenges for the Future *155*
References *157*

8 NMR Spectroscopy as a Versatile Analytical Platform for Toxicology Research *163*
Olivia Corcoran

8.1 A Role for NMR in Toxicogenomics *163*
8.2 Evolution of NMR Technologies in Toxicology Research *164*
8.2.1 Conventional NMR Spectroscopy *165*
8.2.2 Flow NMR Methods *168*
8.2.3 HRMAS NMR of Tissues *170*
8.3 Metabolite Profiling by NMR *170*
8.3.1 Inborn Errors of Metabolism *171*
8.3.2 Reactive Metabolites *172*
8.3.3 Animal Models of Toxicity *173*
8.4 Biomarkers of Toxicity *173*
8.4.1 Organ Toxicity *174*
8.4.2 Forensic and Chemical Warfare Toxicology *175*
8.4.3 Environmental Toxicity *176*
8.5 Improvements in NMR Technology *177*
8.5.1 Sensitivity and Throughput *177*
8.5.2 Integrated NMR Chemical Analyzer *178*
8.5.3 Metabolic and Genetic Profiling *179*
8.6 Conclusions *179*
References *180*

Bioinformatic Tools in Toxicogenomics

9 Generation and Validation of a Reference System for Toxicogenomics DNA Microarray Experiments *187*
Jürgen Cox, Hans Gmünder, Andreas Hohn, and Hubert Rehrauer

9.1 Genomics and DNA Microarrays *187*
9.2 Toxicogenomics *188*
9.2.1 Challenges of Conventional Toxicology Approaches *188*
9.2.2 Opportunities for Genomics *188*
9.3 Processes and Methods for Toxicogenomics *188*
9.3.1 Experimental Design *188*
9.3.2 Data Quality Assessment *189*
9.3.3 Reference Compendium Generation *190*
9.3.4 Classification *191*
9.4 Diagnosis of Microarray Data Quality *191*
9.4.1 Sample Preparation *191*
9.4.2 Dye Incorporation *192*
9.4.3 Distortion *192*
9.4.4 Impurities *193*
9.4.5 Scanner Settings *193*

9.4.6 Automation of Data Quality Control *193*
9.4.7 Preprocessing of Microarray Data *193*
9.5 Generating a Reference Compendium of Compounds *194*
9.5.1 Cross Validation *195*
9.6 Mechanism of Action *198*
9.6.1 Alternative Structuring of Profiling Data *198*
9.6.2 Promoter Analysis *199*
9.6.3 Pathways *199*
9.6.4 Mapping Gene Expression Profiles onto Genomes *199*
9.6.5 *In silico* Comparative Genomics *199*
9.7 Outlook *200*
References 200

10 The Chemical Effects in Biological Systems (CEBS) Knowledge Base *201*
Michael D. Waters, Gary Boorman, Pierre Bushel, Michael Cunningham, Rick Irwin, Alex Merrick, Kenneth Olden, Richard Paules, James K. Selkirk, Stanley Stasiewicz, Ben Van Houten, Nigel Walker, Brenda Weis, Honghui Wan, and Raymond Tennant

10.1 Overview *201*
10.2 NCT Intramural Research *204*
10.3 Toxicogenomics Research Partnerships *206*
10.4 Microarray Analysis *207*
10.5 Implementation of a CEBS Prototype *208*
10.6 Systems Toxicology: Bioinformatics and Interpretive Challenges *210*
10.7 Understanding Functions of Biomarkers *211*
10.7.1 Microarray Expression Profile Analysis *211*
10.7.2 Coevolutional Profile Analysis *212*
10.7.3 Domain Fusion Analysis *213*
10.7.4 Structural Analysis *213*
10.7.5 Text Mining in MEDLINE Based on Literature Profile Comparison *213*
10.7.6 Integrative Analysis *214*
10.8 Phased Development of the CEBS Knowledge Base *214*
10.8.1 CEBS Phase I: Microarray/Gene Expression Data, Toxicology/Pathology Data and Associated Analysis Tools *214*
10.8.2 CEBS Phase II: Protein Expression Database and Metabolomics Datasets *219*
10.8.3 CEBS Phase III: Integrate Microarray/Gene Expression and Protein Expression Databases using a Gene/Protein Group Strategy *220*
10.8.4 CEBS Phase IV: Knowledge Technology *221*
10.9 Conclusions *226*
References 229

11 **Investigating the Effective Range of Agents by Using Integrative Modelling** *233*
Andreas Freier, Ralf Hofestädt, and Thoralf Toepel

11.1 Introduction *233*
11.2 Mathematical Models *235*
11.3 Modelling Molecular Databases *237*
11.3.1 Drug Databases *237*
11.3.2 Pathway Databases *238*
11.3.3 Gene Expression Databases and Others *239*
11.4 Integrative Modelling *240*
11.4.1 Data Preprocessing *241*
11.4.2 Object Oriented Models and Data Integration *241*
11.4.2 Process Oriented Modelling Using Views *244*
11.4.3 System Oriented Modelling and Simulation *246*
11.4.4 Implementation *248*
11.5 Summary *249*
References *250*

12 **Databases and Tools for *in silico* Analysis of Regulation of Gene Expression** *253*
Alexander Kel, Olga Kel-Margoulis, and Edgar Wingender

12.1 Introduction *253*
12.2 Concepts of Gene Regulation *253*
12.2.1 Transcription Factors *254*
12.2.2 Modern Concepts of the Structure and Function of the Gene-regulation Regions in the Genome *255*
12.3 Databases Relating to Gene Regulation *260*
12.3.1 TRANSFAC Database *262*
12.4 Regulatory Sequence-analysis Tools and Approaches *263*
12.4.1 Motif Analysis *264*
12.4.2 Recognition of TF Binding Sites *266*
12.4.3 Recognition of Composite Regulatory Elements *272*
12.4.4 Analysis of Promoters *275*
12.4.5 Functional Classification of Promoters and Prediction of Gene Regulation *279*
12.4.6 Phylogenetic Footprinting *281*
12.5 Analysis of Gene Expression Data *281*
12.5.1 Analysis of the Promoters of Coregulated Genes *282*
References *285*

13 Systems Biology Applied to Toxicogenomics *291*
Klaus Prank, Matthias Höchsmann, Björn Oleson, Thomas Schmidt, Leila Taher, and Dion Whitehead

13.1 Introduction to Systems Biology *291*
13.1.1 System-level Understanding of Biological Systems *294*
13.1.2 Measurement Technology and Experimental Approaches *301*
13.2 Data Mining and Reverse Engineering of Regulatory Networks *305*
13.2.1 Data Mining Techniques *305*
13.2.2 Inferring Gene Regulatory Networks from Gene Expression Data *307*
13.2.3 Reverse Engineering of Metabolic and Signal-transduction Pathways *308*
13.3 Modelling and Simulation Software *310*
13.3.1 Automated Model Generation *310*
13.3.2 Parser *311*
13.3.3 Systems Biology Workbench and Markup Languages *313*
13.3.4 Parameter Estimation *317*
13.3.5 Simulators *318*
13.3.6 Visualization *320*
13.4 Toward Predictive *in silico* Toxicogenomics *320*
13.4.1 A Systems Biology Approach to *ab initio* Hepatotoxicity Testing *320*
13.4.2 *In silico* Toxicogenomics for Personalized Medicine *321*
13.4.3 Future of Predictive *in silico* Toxicity Testing in the R&D Process *321*
References *322*

Application of Toxicogenomic: Case Studies

14 Regulatory Networks of Liver-enriched Transcription Factors in Liver Biology and Disease *327*
Jürgen Borlak, Jürgen Klempnauer, and Harald Schrem

14.1 Introduction *327*
14.2 The HNF-1/HNF-4 Network for Liver-specific Gene Expression *328*
14.2.1 HNF-1 Regulates HNF-4alpha Expression *329*
14.2.2 HNF-1alpha and HNF-4 Regulate HNF-1alpha Expression *329*
14.2.3 Dimerization Cofactor of HNF-1alpha and Liver-specific Gene Expression *331*
14.2.4 Agonistic and Antagonistic Ligands for the Orphan Nuclear Receptor HNF-4alpha *331*
14.2.5 Coactivators for HNF-1 and HNF-4 and Their Network Effects in Liver Biology *334*
14.2.6 The Relevance of HNF-4alpha Splice Variants in Differential Transcriptional Regulation *336*
14.2.7 Activation and Repression by Homo- and Heterodimerization of HNF-4alpha Proteins *336*

14.2.8 Posttranscriptional Modification of HNF-4 Function by Phosphorylation and Acetylation *337*
14.2.9 Cooperation and Competition between COUP-TF and HNF-4 *337*
14.2.10 The Role of HNFs in CYP Monooxygenase Expression *338*
14.3 HNF-6 and HNF-3beta in Liver-specific Transcription Factor Networks *339*
14.3.1 HNF-6, OC-2, HNF-3beta, and C/EBPs Regulate HNF-3beta Expression *339*
14.3.2 Competition and Cooperation between HNF-3alpha and HNF-3beta *340*
14.4 The Role of C/EBPs in Diverse Physiological Functions *340*
14.4.1 C/EBP-alpha in Energy Metabolism and Detoxification *340*
14.4.2 C/EBP-beta in Energy Metabolism *343*
14.4.3 C/EBPs in the Acute-phase Response *344*
14.4.4 Protein–Protein Interactions of C/EBP-beta during the Acute-phase Response *347*
14.4.5 C/EBPs in Liver Regeneration *348*
14.4.6 C/EBPs and Apoptosis *349*
14.4.7 C/EBPs in Liver Development *350*
14.4.8 The Role of C/EBPs in CYP Monooxygenase Expression during Development *350*
14.4.9 C/EBPs and Their Role in Liver Tumour Biology *351*
14.5 Involvement of C/EBP-alpha and C/EBP-beta in Regulation of Cell Cycle Control *352*
14.5.1 C/EBP-alpha Expression and Growth Arrest *352*
14.5.2 Glucocorticoid-induced G1 Cell Cycle Arrest Is Mediated by C/EBP-alpha *352*
14.5.3 Protein–Protein Interactions between p21, cdk2, cdk4, and C/EBP-alpha *354*
14.5.4 C/EBP-alpha and p107 Protein–Protein Interaction Disrupts E2F Complexes *355*
14.5.5 C/EBP-beta Arrests the Cell Cycle before the G1/S Boundary *356*
14.6 DBP Circadian Gene Regulation in the Liver *356*
14.7 Conclusions and Outlook *358*
References *360*

15 Toxicogenomics Applied to Understanding Cholestasis and Steatosis in the Liver *369*
Timothy W. Gant, Peter Greaves, Andrew G. Smith, and Andreas Gescher

15.1 Introduction *369*
15.2 Models of Cholestatsis and Steatosis *370*
15.2.1 The *Fech Mouse* *370*
15.2.2 Griseofulvin *371*
15.2.3 ET743 *371*
15.2.4 Alpha-napthylisothiocyanate (ANIT) *371*

15.3 Pathological and Biochemical Characterization of the Models *372*
15.3.1 Pathological Characterization *372*
15.3.2 Protoporphyrin IX levels in Models of Ferrochelatase Inhibition *374*
15.4 Microarray and Bioinformatics Methodology *375*
15.5 Liver Gene Expression Altered Directly as a Response to Griseofulvin *377*
15.5.1 Genes of the Heme Synthesis and Catabolism Pathways *377*
15.5.2 Monooxygenases *380*
15.6 Gene Expression Changes Associated with Pathological Changes *381*
15.6.1 Gene Expression Associated with Inflammation *381*
15.6.2 CD24a *383*
15.6.3 Annexins and Liver Damage or Maybe Cholestasis? *383*
15.6.4 Fibrosis and Mallory Body Formation *383*
15.7 Gleaning New Information on Pathological Changes from Gene Expression Data *387*
15.8 Conclusions *389*
References *392*

16 Toxicogenomics Applied to Cardiovascular Toxicity *395*
Thomas Thum and Jürgen Borlak

16.1 Introduction *395*
16.2 Toxicogenomics Applied to Cardiovascular Toxicity *395*
16.2.1 Drug-induced Cardiac Arrhythmias *395*
16.2.2 Drug-induced Myocardial Apoptosis and Necrosis *396*
16.2.3 Drug-induced Cardiomyopathy and Myocardial Remodelling *398*
16.2.4 Drug-induced Myocarditis and Inflammation *399*
16.2.5 Drug-induced Effects on Cardiac Contractility *399*
16.2.6 Drug-induced Cardiac Hypertrophy *399*
16.2.7 Drug-induced Vascular Injury *400*
16.3 Environmental Pollution and Cardiotoxicity: Effect of Halogenated Aromatic Hydrocarbons *401*
16.4 Importance of Single Nucleotide Polymorphisms (SNPs) and Tissue-specific Drug Metabolism in Cardiovascular Drug Therapy *402*
16.4.1 Single Nucleotide Polymorphisms and Drug Treatment of Cardiovascular Diseases *402*
16.4.2 Tissue-specific Metabolism in Cardiovascular Tissues *405*
16.5 Conclusions *405*
References *406*

17 Toxicogenomics Applied to Endocrine Disruption *413*
Damian G. Deavall, Jonathan G. Moggs, and George Orphanides

17.1 Introduction *413*
17.1.1 Introduction to Endocrine Disruption *413*
17.1.2 Therapeutic Endocrine Modulators *415*

17.2 Molecular Mechanisms of Estrogen Signalling *416*
17.2.1 Introduction to Estrogen Receptor Action *417*
17.2.2 Extranuclear Action of Estrogen Receptors Signalling Through Kinase Cascades to Pleiotropic Transcriptional Effects *417*
17.3 Current Methods for Assessing Endocrine-disrupting Potential *418*
17.3.1 Nuclear Receptor Binding Assays and Yeast Transactivation Assays *418*
17.3.2 End-point In-vivo Assays for Potential Endocrine Disruptors *419*
17.4 Value of Toxicogenomic Platforms to ED Toxicology *420*
17.4.1 Genome-scale Microarray Experiments Facilitate a Global View of Gene Expression *420*
17.4.2 Experimental Design *424*
17.5 Data Interpretation *425*
17.5.1 The Use of Hierarchical Gene Clustering to Fingerprint ED Modes of Action Will Allow Mechanistic Determination *425*
17.5.2 Pathway Analysis of ED Action *426*
17.5.3 Predictive Testing of ED Potential Based on Transcript Profiling *428*
17.6 Summary *429*
References *430*

18 Toxicogenomics Applied to Teratogenicity Studies *435*
Philip G. Hewitt, Peter-J. Kramer, and Jürgen Borlak

18.1 Introduction *435*
18.1.1 Current Testing Strategies: Established Procedures *438*
18.1.2 Calcium Signalling and Foetal Development *439*
18.1.3 Effect of Dose on Embryo Development *440*
18.1.4 Effect of Time on Embryo Development *441*
18.1.5 Issues Linked to the Placenta as a Barrier *441*
18.1.6 Effect of Xenobiotic and Endogenous Metabolism *442*
18.1.7 Mechanisms of Teratogenicity *443*
18.2 Alternative Methods *443*
18.2.1 Embryonic Stem Cells *443*
18.2.2 Micromasses and Other Cell Culture Systems *444*
18.2.3 Whole-embryo Culture *444*
18.2.4 Gene Expression Profiling *445*
18.2.5 In Silico Studies *445*
18.3 Molecular Aspects of Teratogenicity *445*
18.3.1 Genes Responsible for Causing Birth Defects *445*
18.3.2 Specific Genes Involved in Birth Defects *447*
18.4 Case Study: Elucidation of Mechanisms of Teratogenic Toxicity of the Developmental Drug EMD 82571 *448*
18.4.1 Properties of EMD 57033 and EMD 82571 *448*
18.4.2 Hypothesis-driven Gene Expression Array *450*
18.4.3 Global Expression Array (Affymetrix) *453*
18.4.4 Results and Discussion *454*

18.5 Importance of Surrogate Markers for Prediction of Teratogenicity *464*
18.6 Summary and Future of Gene Expression Profiling for Teratogenicity Studies *464*
References *465*

19 Toxicogenomics Applied to Nephrotoxicity *471*
Anke Lühe and Heinz Hildebrand

19.1 Brief Survey of Nephrotoxicity *471*
19.1.1 Relevance and Occurrence of Nephrotoxic Effects *471*
19.1.2 Different Modes of Nephrotoxicity *472*
19.1.3 Actual Situation in Diagnosis and Mechanistic Investigation *474*
19.1.4 New Perspectives Offered by Toxicogenomics *475*
19.2 Toxicogenomic Approaches in Prediction of Toxicity and Mechanistic Studies (Case Studies) *476*
19.2.1 Prediction of Toxicity: Toxicogenomics Aimed at the Identification of Markers of Renal Toxicity ('Fingerprinting') *476*
19.2.2 Mechanistic Studies: Toxicogenomics Aimed at Elucidating the Mode of Nephrotoxic Action *478*
19.3 Perspectives *483*
References *484*

20 Toxicogenomic Analysis of Human Umbilical Cords to Establish a New Risk Assessment of Human Foetal Exposure to Multiple Chemicals *487*
Masatoshi Komiyama and Chisato Mori

20.1 Introduction *487*
20.2 Strategy for Establishment of a New Risk-assessment Method for Human Foetal Exposure to Multiple Chemicals *488*
20.3 Concentrations of Chemicals in Umbilical Cords of Neonates in Japan *490*
20.4 Gene Expression in Umbilical Cords *491*
20.5 Toxicogenomic Analysis of Human Umbilical Cords *494*
20.5.1 Principal Components Analysis *495*
20.5.2 Hierarchical Cluster Analysis *495*
20.5.3 Relation between Chemical Concentration and Gene Expression in Umbilical Cords *497*
20.5.4 Genes Contributing to Grouping of the Umbilical Cords *499*
20.6 Conclusions *502*
References *503*

21 Genetic Variability: Implications for Toxicogenomic Research *507*
Gilbert Schönfelder, Dieter Schwarz, Thomas Gerloff, Martin Paul, and Ivar Roots

21.1 Introduction *507*
21.2 Toxicity Due to Genetic Variability of Xenobiotic-metabolizing Enzymes *508*
21.2.1 Genetic Variability in Carcinogen Activation by CYP450 Enzymes *509*
21.2.2 Toxicity by Variants of Thiopurine Methyltransferase (TPMT) *517*
21.2.3 Dihydropyrimidine Dehydrogenase *518*
21.2.4 UDP-glucuronosyl Transferase Enzymes *520*
21.3 Involvement of Xenobiotic Transporter Systems in Toxicogenomics *521*
21.3.1 MDR1 (ABCB1) *522*
21.3.2 Multidrug Resistance-related Proteins (MRPs, ABCC) *525*
References *527*

22 Profiling of Peripheral Blood Gene Expression to Search for Biomarkers *535*
Arno Kalkuhl and Mario Beilmann

22.1 Introduction *535*
22.2 Objective *536*
22.3 Methods *537*
22.3.1 Animal Study *537*
22.3.2 RNA Isolation *538*
22.3.3 Differential Gene Expression Analysis and Statistics *539*
22.4 Results and Discussion *540*
22.4.1 Comparison of Analyzing Two Different Blood Cell Populations *540*
22.4.2 Hemogram/Histopathology in the Animal Study *542*
22.4.3 Analysis of the Number of Significantly Deregulated Genes *542*
22.4.4 Analysis of Deregulated Genes in Blood after Cyclosporin A Administration *545*
22.4.5 Analysis of Genes Deregulated in Blood and Target Organ *551*
22.5 Summary *556*
References *556*

23 How Things Could Be Done Better Using Toxicogenomics: A Retrospective Analysis *561*
Laura Suter and Rodolfo Gasser

23.1 Introduction *561*
23.2 Case Example: Two 5-HT_6 Receptor Antagonists Displaying Similar Pharmacological Activity and Different Toxicity Profiles *562*
23.2.1 Pharmacological Characteristics of the Compounds *562*
23.2.2 Toxicological Findings in Rats and Dogs *563*

23.3 The use of Toxicogenomics (Retrospectively) to Evaluate Hepatic Liability 564
23.4 Classification of Compounds with the Use of a Reference Gene Expression Database 566
23.4.1 Differentiation of Two Pharmacologically Closely Related Compounds 567
23.4.2 Use of Gene Expression for Mechanistic Hypothesis Generation 569
23.4.3 Corroboration of the Mechanistic Hypothesis I: Validation of the Technology 573
23.4.4 Corroboration of the Mechanistic Hypothesis II: *in vitro* Studies 575
23.5 Conclusions and Outlook 578
References 581

24 Toxicogenomics Applied to Hematotoxicology 583
Yoko Hirabayashi and Tohru Inoue

24.1 Introduction: Forward and Reverse Genomics 583
24.2 Hematopoietic Stem/Progenitor Cells in Hematotoxicology 585
24.3 Molecular Signature of Stemness of Hematopoietic Stem/Progenies 588
24.4 Radiation Hematotoxicity and Leukemogenesis 591
24.4.1 Radiation Effects on Hematopoietic Stem/Progenitor Cells 591
24.4.2 Radiation Exposure and Gene Expression Microarray 593
24.5 Benzene-induced Hematotoxicity and Leukemogenesis 594
24.5.1 Benzene Exposure and Cell Cycle in Hematopoietic Stem/Progenitor Cells 594
24.5.2 Gene-expression Profile after Benzene Exposure in WT Mice 596
24.5.3 Cell-cycle–related Genes in p53 KO and WT Mice 598
24.5.4 Apoptosis-related Genes in p53 KO and WT Mice 601
24.5.5 DNA-repair–related Genes in the p53 Gene Network 601
24.6 Summary 602
References 604

The National Toxicogenomic Program / Initiatives

25 The National Toxicogenomics Program 611
James K. Selkirk, Michael D. Waters, and Raymond W. Tennant

25.1 Introduction: The National Center for Toxicogenomics 611
25.2 Risk Assessment 613
25.3 The NCT Strategy 614
25.4 Toxicogenomics Broadly Defined 615
25.5 The Chemical Effects in Biological Systems (CEBS) Knowledge Base 617
25.6 Conclusions 618
References 619

26 Toxicogenomics: Japanese Initiative *623*
Tetsuro Urushidani and Taku Nagao

26.1 The Present State of Drug Development Genome Science *623*
26.2 The Necessity of Toxicogenomics *625*
26.3 Toxicogenomics Project 2002–2007 *626*
26.3.1 Planning Process and the Present Organization *626*
26.3.2 Contents of the Project *627*
26.3.3 Advantage and Originality of the Project *629*
26.4 Future Perspectives and Conclusions *630*
References *631*

Point of View from Regulatory Authorities and Ethical Aspects

27 Toxicogenomics in Need of an ICH Guideline? Experiences from the Past *635*
Frauke Meyer and Gerd Bode

27.1 Introduction *635*
27.2 Application Options for Toxicogenomics *636*
27.2.1 Comparative/Predictive Toxicogenomics *636*
27.2.2 Mechanistic Studies (Mode of Action) *637*
27.2.3 Risk Assessment *637*
27.2.4 Dose-dependent Toxicity *638*
27.2.5 Interspecies Extrapolation *638*
27.2.6 Human Biomarkers of Exposure *638*
27.2.7 Regulatory Acceptance: Current Status *639*
27.3 ICH Process for Harmonization of Guidelines: Experience from the Past *640*
27.3.1 Overview *640*
27.3.2 ICH Carcinogenicity Guidelines as a Case Study: Experience with the Implementation of Alternative Models in Cancer Risk Assessment *641*
27.4 Incorporation of Toxicogenomics into Drug Development, Evaluation, and Regulation: Benefits versus Risks *645*
27.4.1 General Criteria for Successful Exploitation *645*
27.4.2 Evaluation Process: Current Status *651*
27.5 Summary and Outlook *653*
References *655*

Subject Index *657*